AU2013255456B2 - Method - Google Patents

Method Download PDF

Info

Publication number
AU2013255456B2
AU2013255456B2 AU2013255456A AU2013255456A AU2013255456B2 AU 2013255456 B2 AU2013255456 B2 AU 2013255456B2 AU 2013255456 A AU2013255456 A AU 2013255456A AU 2013255456 A AU2013255456 A AU 2013255456A AU 2013255456 B2 AU2013255456 B2 AU 2013255456B2
Authority
AU
Australia
Prior art keywords
akt3
emt
expression
subject
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013255456A
Other languages
English (en)
Other versions
AU2013255456A1 (en
Inventor
Jim LORENS
Crina TIRON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BerGenBio ASA
Original Assignee
BerGenBio ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BerGenBio ASA filed Critical BerGenBio ASA
Publication of AU2013255456A1 publication Critical patent/AU2013255456A1/en
Assigned to BERGENBIO ASA reassignment BERGENBIO ASA Alteration of Name(s) of Applicant(s) under S113 Assignors: BERGENBIO AS
Application granted granted Critical
Publication of AU2013255456B2 publication Critical patent/AU2013255456B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
AU2013255456A 2012-05-02 2013-05-02 Method Ceased AU2013255456B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261641512P 2012-05-02 2012-05-02
GB1207722.8 2012-05-02
US61/641,512 2012-05-02
GB201207722A GB201207722D0 (en) 2012-05-02 2012-05-02 Method
PCT/IB2013/053488 WO2013164788A2 (en) 2012-05-02 2013-05-02 Method

Publications (2)

Publication Number Publication Date
AU2013255456A1 AU2013255456A1 (en) 2014-11-13
AU2013255456B2 true AU2013255456B2 (en) 2018-07-26

Family

ID=46330714

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013255456A Ceased AU2013255456B2 (en) 2012-05-02 2013-05-02 Method

Country Status (13)

Country Link
US (2) US10317405B2 (enExample)
EP (1) EP2845004A2 (enExample)
JP (2) JP2015525060A (enExample)
KR (1) KR102179389B1 (enExample)
CN (1) CN104335046B (enExample)
AU (1) AU2013255456B2 (enExample)
BR (1) BR112014027219A2 (enExample)
CA (1) CA2871352A1 (enExample)
EA (1) EA201401201A1 (enExample)
GB (1) GB201207722D0 (enExample)
IN (1) IN2014MN02114A (enExample)
SG (1) SG11201407032WA (enExample)
WO (1) WO2013164788A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016011052A1 (en) * 2014-07-14 2016-01-21 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
GB201420239D0 (en) * 2014-11-14 2014-12-31 Bergenbio As Biomarker
GB201512133D0 (en) * 2015-07-10 2015-08-19 Bergenbio As Biomarkers
KR101941054B1 (ko) * 2016-07-20 2019-01-23 연세대학교 산학협력단 암 예후 예측을 위한 조성물 및 이를 포함하는 키트
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
KR102080384B1 (ko) * 2018-02-28 2020-02-21 주식회사 마크로젠 암줄기세포 특이적 바이오마커
SG11202104963WA (en) * 2018-11-12 2021-06-29 Agency Science Tech & Res Methods for manipulating cell state transitions in cancer
US20230181563A1 (en) * 2020-05-08 2023-06-15 Georgiamune Llc Akt3 modulators and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6809194B1 (en) 2000-05-10 2004-10-26 Chiron Corporation Akt3 inhibitors
US20040121413A1 (en) 2002-12-20 2004-06-24 Aebersold Rudolf H. Androgen-regulated genes and uses for diagnosis, prognosis and treatment of prostate neoplastic conditions
WO2004086038A2 (en) * 2003-03-28 2004-10-07 Institut Curie A method for screening compounds having the capacity to control tumor cell invasion or metastasis using constitutively active akt
ATE446752T1 (de) * 2003-04-24 2009-11-15 Merck & Co Inc Hemmer der akt aktivität
WO2008042867A2 (en) * 2006-09-29 2008-04-10 Emiliem Inc. Modulators of multiple kinases
EP2114983B8 (en) 2007-02-07 2015-02-18 The Regents of the University of Colorado, A Body Corporate Axl tyrosine kinase inhibitors and methods of making and using the same
MX2010000474A (es) * 2007-07-12 2010-06-23 Univ South Florida Inhibidores de proteina serina/treonina quinasa a/proteina quinasa b con actividad antitumoral.
WO2009025847A2 (en) * 2007-08-21 2009-02-26 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US8735064B2 (en) 2007-12-24 2014-05-27 Bergenbio As Methods for creating and identifying functional RNA interference elements
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
PT2387395E (pt) 2009-01-16 2015-02-04 Rigel Pharmaceuticals Inc Inibidores de axl para utilização em terapia de combinação para prevenir, tratar ou gerir cancro metastático
WO2010091354A2 (en) 2009-02-06 2010-08-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Akt tyrosine 176 phosphorylation cancer biomarker
SG174356A1 (en) * 2009-03-13 2011-10-28 Bergen Teknologioverforing As Methods using axl as a biomarker of epithelial-to-mesnchymal transition
WO2010115119A2 (en) 2009-04-02 2010-10-07 Tufts Medical Center, Inc. Compositions and methods for diagnosis and prognosis of cancer and progression, and for screening anti-cancer agents
US8673572B2 (en) 2009-10-23 2014-03-18 The Translational Genomics Research Institute Methods used in identifying glioblastoma
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
EP2913405B1 (en) 2010-07-27 2016-11-09 Genomic Health, Inc. Method for using gene expression to determine prognosis of prostate cancer
US20130171159A1 (en) * 2010-09-10 2013-07-04 Brian Arthur Hemmings Phosphorylated twist1 and metastasis
US20140030255A1 (en) * 2010-11-03 2014-01-30 Merck Sharp & Dohme Corp. Methods of predicting cancer cell response to therapeutic agents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
NAKATANI KANAME ET AL, "Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 31, pages 21528-21532. *
NICOLE GRABINSKI ET AL, "Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells", CELLULAR SIGNALLING, vol. 23, no. 12, pages 1952-1960. *
STAHL J M ET AL, "Deregulated Akt3 activity promotes development of malignant melanoma", CANCER RESEARCH, vol. 64, no. 19, , pages 7002-7010. *
ZEISBERG MICHAEL and NEILSON ERIC. G., "Biomarkers for epithelial-mesenchymal transitions", THE JOURNAL OF CLINICAL INVESTIGATION, 2009, vol. 119, no. 6, pages 1429-1437. *

Also Published As

Publication number Publication date
GB201207722D0 (en) 2012-06-13
IN2014MN02114A (enExample) 2015-09-04
KR20150016518A (ko) 2015-02-12
US20200072839A1 (en) 2020-03-05
US20150119475A1 (en) 2015-04-30
EA201401201A1 (ru) 2015-02-27
SG11201407032WA (en) 2014-11-27
JP2017136077A (ja) 2017-08-10
CN104335046B (zh) 2019-10-11
JP6738755B2 (ja) 2020-08-12
WO2013164788A2 (en) 2013-11-07
EP2845004A2 (en) 2015-03-11
CA2871352A1 (en) 2013-11-07
KR102179389B1 (ko) 2020-11-18
US10317405B2 (en) 2019-06-11
JP2015525060A (ja) 2015-09-03
WO2013164788A3 (en) 2014-01-23
CN104335046A (zh) 2015-02-04
AU2013255456A1 (en) 2014-11-13
BR112014027219A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
US20200072839A1 (en) Method
JP6912538B2 (ja) 血中循環腫瘍細胞に関する方法およびアッセイ
EP2406397B1 (en) Methods using axl as a biomarker of epithelial-to-mesenchymal transition
Ghoreishy et al. Exosomal microRNA and stroke: a review
JP6587288B2 (ja) がん幹細胞の同定ならびに診断および処置のためのその使用
KR101615424B1 (ko) 마이크로알엔에이를 표적으로 하는 신경변성 질환 예방 또는 치료용 약학 조성물 및 방법
US11035008B2 (en) Biomarkers for cancer
US20170314077A1 (en) Slfn11 as biomarker for aml
KR101204620B1 (ko) 혈관 형성 관련 질환 진단용 마커 및 이의 용도
US10416163B2 (en) Method and treatment of recurring endometrial cancer with an inhibitor of USP14
CN111630185A (zh) 包含pmvk作为活性成分的用于诊断耐放射癌症或预测放射疗法预后的生物标志物组合物
KR101150410B1 (ko) 간암 진단용 마커로서의 ｓ100ｐ의 용도
Mele The role of StAR-D3 in HER2 overexpressing breast cancer

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: BERGENBIO ASA

Free format text: FORMER NAME(S): BERGENBIO AS

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired